$966 Billion is the total value of Casdin Capital, LLC's 33 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ONCE | Sell | SPARK THERAPEUTICS INC | $83,722,834,000 | -7.6% | 863,300 | -2.4% | 8.66% | +2.2% |
| MYOK | Sell | MYOKARDIA INC | $58,147,250,000 | -9.8% | 1,115,000 | -13.2% | 6.02% | -0.2% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $48,252,000,000 | +2.3% | 600,000 | -7.7% | 4.99% | +13.1% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $24,157,400,000 | -33.9% | 860,000 | -10.9% | 2.50% | -26.9% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $13,167,750,000 | -20.1% | 1,455,000 | -4.9% | 1.36% | -11.6% |
| EDIT | Sell | EDITAS MEDICINE INC | $9,437,100,000 | -20.5% | 415,000 | -13.5% | 0.98% | -12.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-01-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.